Thank you very much, Mr. Chair.
My first question is for Dr. Dutt in regard to pharmacare.
With regard to pharmacare, it's something that I personally think we need to move towards, but the implementation of it is critical. I'm wondering if you or your organization have given much thought to the implementation of it. For example, one of the criticisms in the U.S. with regard to the current systems there is that the insurance companies negotiate the prices for the medications themselves, so doctors end up spending a lot of time fighting with insurance companies to cover other brands, or let's say, the non-generic brands.
Has your organization given much thought to creating that protection so that if a physician prescribes a certain medication, the patient can actually get it, versus just whatever is negotiated at the onset?